Abstract
Sarcomas are a class of tumors defined by their mesenchymal origin that comprise very different neoplasms. Although some sarcomas harbor pathogenomic molecular alterations (i.e. specific balanced translocations and their associated chimeric fusion genes), others still lack an ultimate diagnostic tool, which could be of great interest as in some cases different sarcomas share a similar clinical manifestation. High throughput tools are contributing new ways to molecularly delineate the boundaries of each sarcoma subtype. Moreover, they are also shedding light into other research subjects of immediate concern: (i) the elucidation of the molecular targets of chimeric fusion proteins and their interactome; (ii) the discovery of new biomarkers and therapeutic targets; and (iii) the delineation of the response to therapeutic agents. Here we review the application of proteomics approaches to sarcomas, with special emphasis in Ewing sarcoma. Proteomics strategies offer the focus, the analytical potential, and the high throughput capabilities to decipher the hidden agenda of the biology of sarcomas, a knowledge that will surely be the subject of future patents intended to develop new diagnostic and therapeutic tools.
Keywords: 2-DE, Cancer, cell signaling, chimeric fusion protein, chromosomal translocation, diagnostic tools, DIGE, Ewing sarcoma, EWS-FLI1, MALDI-ToF, mass spectrometry, molecular targets, oncogene, protein microarrays, proteomics, sarcomas, sarcomagenesis, targets of therapy.
Recent Patents on Biotechnology
Title:Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Volume: 7 Issue: 2
Author(s): Carlos Mackintosh and Juan Madoz-Gúrpide
Affiliation:
Keywords: 2-DE, Cancer, cell signaling, chimeric fusion protein, chromosomal translocation, diagnostic tools, DIGE, Ewing sarcoma, EWS-FLI1, MALDI-ToF, mass spectrometry, molecular targets, oncogene, protein microarrays, proteomics, sarcomas, sarcomagenesis, targets of therapy.
Abstract: Sarcomas are a class of tumors defined by their mesenchymal origin that comprise very different neoplasms. Although some sarcomas harbor pathogenomic molecular alterations (i.e. specific balanced translocations and their associated chimeric fusion genes), others still lack an ultimate diagnostic tool, which could be of great interest as in some cases different sarcomas share a similar clinical manifestation. High throughput tools are contributing new ways to molecularly delineate the boundaries of each sarcoma subtype. Moreover, they are also shedding light into other research subjects of immediate concern: (i) the elucidation of the molecular targets of chimeric fusion proteins and their interactome; (ii) the discovery of new biomarkers and therapeutic targets; and (iii) the delineation of the response to therapeutic agents. Here we review the application of proteomics approaches to sarcomas, with special emphasis in Ewing sarcoma. Proteomics strategies offer the focus, the analytical potential, and the high throughput capabilities to decipher the hidden agenda of the biology of sarcomas, a knowledge that will surely be the subject of future patents intended to develop new diagnostic and therapeutic tools.
Export Options
About this article
Cite this article as:
Mackintosh Carlos and Madoz-Gúrpide Juan, Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight, Recent Patents on Biotechnology 2013; 7 (2) . https://dx.doi.org/10.2174/18722083113079990004
DOI https://dx.doi.org/10.2174/18722083113079990004 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Antitumour Activity of the Primin (2-methoxy-6-n-pentyl-1,4-benzoquinone) and Analogues
Medicinal Chemistry Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Glycosyltransferases, Important Tools for Drug Design
Current Topics in Medicinal Chemistry Nucleic Acids Electrotransfer In Vivo: Mechanisms and Practical Aspects
Current Gene Therapy The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review
Current Medicinal Chemistry Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Research in Rare Diseases - When Less is More
Current Medicinal Chemistry